Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sunil Rayan

Vascular Surgery Encinitas, CA Medical Doctor

NPI 1174606016 CMS profile 325756

320 Santa Fe Dr, Ste 212, Encinitas, CA 92024

Open in the dashboard

General payments

$26,530

206 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sunil Rayan of Encinitas, CA is reported in the CMS Open Payments database as having received $26,530 across 206 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,459 37
2024 General $1,704 34
2023 General $1,485 30
2022 General $3,658 27
2021 General $5,259 25
2020 General $3,827 17
2019 General $7,138 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sunil Rayan
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Sunil Rayan were reported at $3,459. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Sunil Rayan Vascular Surgery median Middle half National median
2019 $7,138 $796 $226–$2,363 $163
2020 $3,827 $348 $118–$1,110 $114
2021 $5,259 $471 $158–$1,421 $132
2022 $3,658 $725 $222–$2,183 $149
2023 $1,485 $836 $257–$2,440 $160
2024 $1,704 $909 $252–$2,619 $164
2025 $3,459 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endologix, Inc. $20,729 41 payments
  2. Medtronic, Inc. $1,533 59 payments
  3. Silk Road Medical, Inc. $1,088 18 payments
  4. W. L. Gore & Associates, Inc. $603 14 payments
  5. Boston Scientific Corporation $558 14 payments
  6. AngioDynamics, Inc. $349 7 payments
  7. Medtronic USA, Inc. $269 3 payments
  8. Abbott Laboratories $175 4 payments
  9. Cook Medical LLC $172 3 payments
  10. Titan Spine, LLC $106 1 payment
  11. Other $948 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $16,800 17 payments
  2. Food and Beverage $9,684 188 payments
  3. Education $46 1 payment
Products named General payments · program years 2019–2025
  1. AFX $9,261 14 payments
  2. Ovation $8,558 15 payments
  3. Alto Abdominal Stent Graft System $8,137 16 payments
  4. AFX2 Bifurcated Endograft System $3,671 7 payments
  5. ENROUTE Transcarotid Stent $779 13 payments
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $779 13 payments
  7. ENDOCROSS Device $664 3 payments
  8. Torus Stent Graft System $664 3 payments
  9. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $489 6 payments
  10. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $489 6 payments
  11. Other $6,412 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

279

Median for Vascular Surgery: 122

Drug cost

$22,113

Median for Vascular Surgery: $14,135

Branded share of claims

75.6%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 23 $13,253
Xarelto Rivaroxaban Brand 11 $6,952
Clopidogrel Clopidogrel Bisulfate Brand 152 $1,167
Tamsulosin Hcl Generic 44 $393
Finasteride Generic 24 $277
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 25 $71

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$848,486

Of which drugs: $189

Medicare patients

608

Average age 77

Services billed

3,665

310 women, 298 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 42%
Chronic kidney disease 35%
Atrial fibrillation 34%
Diabetes 29%
Heart failure 27%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 43 1,828 $189

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

206 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record